Strategic Wealth Partners Ltd. Boosts Stock Position in Pfizer Inc. (NYSE:PFE)

Strategic Wealth Partners Ltd. increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 22.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,234 shares of the biopharmaceutical company’s stock after purchasing an additional 3,125 shares during the quarter. Strategic Wealth Partners Ltd.’s holdings in Pfizer were worth $442,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Parsons Capital Management Inc. RI grew its stake in Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock worth $7,820,000 after purchasing an additional 159,984 shares in the last quarter. Mcdonald Partners LLC grew its stake in Pfizer by 9.9% during the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock worth $2,926,000 after purchasing an additional 9,963 shares in the last quarter. Merit Financial Group LLC grew its stake in Pfizer by 60.8% during the 4th quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company’s stock worth $3,395,000 after purchasing an additional 48,397 shares in the last quarter. Bank of Jackson Hole Trust acquired a new position in Pfizer during the 4th quarter worth $264,000. Finally, Amplius Wealth Advisors LLC grew its stake in Pfizer by 80.7% during the 4th quarter. Amplius Wealth Advisors LLC now owns 46,823 shares of the biopharmaceutical company’s stock worth $1,242,000 after purchasing an additional 20,911 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on PFE shares. UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Stock Up 1.0%

PFE opened at $22.83 on Monday. The business has a 50 day moving average price of $23.65 and a two-hundred day moving average price of $25.32. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market cap of $129.77 billion, a PE ratio of 16.19, a P/E/G ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.82 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.54%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.